Tenaliwin-M – Teneligliptin 20mg + Metformin SR 500mg Tablets (10’s) | Diabetes Combination Therapy

Description

Tenaliwin-M Tablets (10’s) | Teneligliptin 20mg + Metformin SR 500mg | For Type 2 Diabetes Management

Category: Anti-diabetic Combination Therapy
Pack Size: 10 Sustained-Release Tablets (Blister Pack)

Composition (Per Tablet):

• Teneligliptin 20mg (DPP-4 Inhibitor – Enhances Incretin Effect)

• Metformin Hydrochloride SR 500mg (Sustained-Release Biguanide – Insulin Sensitizer)

Key Benefits:
✔️ Dual-Mechanism Action: Targets both insulin resistance and insulin secretion
✔️ Sustained-Release Metformin: Reduces GI side effects for better tolerance
✔️ Low Hypoglycemia Risk: Glucose-dependent mechanism of teneligliptin
✔️ Renal Advantage: Teneligliptin requires no dose adjustment in renal impairment

Therapeutic Uses:
• Type 2 diabetes mellitus inadequately controlled on monotherapy
• Patients requiring both insulin sensitization and incretin enhancement
• Those intolerant to immediate-release metformin formulations

Dosage (Adults):

• 1 tablet twice daily with meals

• Swallow whole – do not crush or chew

• Maximum: 2 tablets twice daily (under medical supervision)

Safety Profile:
🚫 Contraindications:

• Type 1 diabetes mellitus

• Diabetic ketoacidosis

• Severe renal impairment (eGFR <30 mL/min)

• Metabolic acidosis

⚠️ Monitor For:
• Gastrointestinal discomfort (usually transient)
• Vitamin B12 deficiency with long-term use
• Signs of lactic acidosis (rare but serious)

Drug Interactions:
▲ Significant Interactions:

• Iodinated contrast media (temporary discontinuation needed)

• Alcohol (increased lactic acidosis risk)

• Corticosteroids (reduced glycemic control)

Storage:

• Below 30°C

• Protect from moisture

• Keep in original packaging